ABCB1 C3435T

The Efflux Pump That Doesn't Change — But Everything Changes Anyway

P-glycoprotein is your body's master bouncer, stationed at critical barriers —
the gut, liver, kidneys, blood-brain barrier — pumping hundreds of drugs and
toxins back out before they can accumulate. The ABCB1 gene | Also known as
MDR1 (multidrug resistance 1), this gene encodes a 1280-amino-acid
transmembrane pump on chromosome 7
creates this ATP-dependent efflux transporter, determining how much of a drug
actually reaches its target versus getting ejected back into circulation.
C3435T is a synonymous variant — same amino acid (isoleucine at position 1145),
different nucleotide — yet it profoundly alters P-gp expression and function.

The Mechanism: When Silence Isn't Silent

Despite encoding the same amino acid, the T variant creates a rare codon |
Less frequently used in human protein synthesis, slowing translation
rate that changes how the mRNA
folds during translation. Wang et al. demonstrated | Using allele-specific
expression analysis in human liver samples
that the 3435T allele produces less stable mRNA (C/T ratios 1.06-1.61),
reducing P-gp expression by altering mRNA secondary structure. The result:
AA homozygotes have 30-50% lower intestinal P-gp expression than GG carriers,
leading to higher plasma drug levels for P-gp substrates after oral
administration.

Kimchi-Sarfaty's group showed | Published in Science
2007 that the synonymous change
also alters co-translational protein folding, creating a P-gp structure with
different substrate specificity despite similar protein levels. The rare codon
slows translation, giving the nascent protein extra time to fold differently,
changing which drugs fit the efflux pump.

The Evidence: Hundreds of Drugs, Inconsistent Results

The Hoffmeyer study | 2000 landmark paper with 21 healthy
volunteers first reported that TT
homozygotes had significantly lower duodenal P-gp expression and 1.5-fold
higher plasma digoxin concentrations compared to GG homozygotes. Since then,
hundreds of studies have examined C3435T effects on drug disposition, with
maddeningly inconsistent results.

For immunosuppressants: Haufroid et al. (n=100 renal transplant
patients) found AA carriers needed
lower tacrolimus doses to achieve target levels, though effects were modest
compared to CYP3A5 polymorphisms. Meta-analyses show small but significant
associations with cyclosporine pharmacokinetics, though clinical utility remains
debated.

For antidepressants: Saiz-Rodríguez et al. (n=473 healthy
volunteers) found TT individuals
showed lower olanzapine clearance but enhanced elimination of risperidone and
trazodone, suggesting drug-specific effects. The authors concluded that C3435T
affects some CNS drugs but that ABCB1 haplotypes (combinations with rs1128503
and rs2032582) may be more predictive than single SNPs.

The inconsistency stems from several factors: C3435T is in strong linkage
disequilibrium | Two SNPs inherited together more often than by
chance with rs1128503
(C1236T) and rs2032582 (G2677T/A), forming common haplotypes. Drug response
depends on substrate-specific affinity for different P-gp conformations.
CYP3A4/5 metabolism often matters more than P-gp transport. Tissue-specific
effects vary (intestine vs. blood-brain barrier). PharmGKB assigns Level 3
evidence (single or non-replicated studies) for most C3435T-drug pairs.

Practical Implications: Know Your Substrates

P-glycoprotein handles hundreds of structurally diverse
substrates: cardiac drugs
(digoxin, verapamil, diltiazem), immunosuppressants (cyclosporine, tacrolimus),
cancer chemotherapy (doxorubicin, vincristine, paclitaxel, imatinib),
antiretrovirals (ritonavir, saquinavir), opioids (morphine, fentanyl,
methadone), antihistamines (fexofenadine), and many others.

The AA genotype generally means higher drug bioavailability (more gets in) but
also higher CNS penetration and potentially more side effects. However, the
clinical significance varies dramatically by drug, dose, and individual. For
narrow therapeutic index drugs like digoxin or immunosuppressants, even modest
effects matter. For most other medications, dose adjustments based on clinical
response (therapeutic drug monitoring) outweigh genetic prediction.

Interactions: The Haplotype Matters More

C3435T rarely acts alone. It forms two major haplotypes with rs1128503 (C1236T)
and rs2032582 (G2677T/A): the reference haplotype (C-G-C, designated ABCB1*1)
and the variant haplotype (T-T-T, designated ABCB1*13). Studies increasingly
show that haplotype analysis predicts drug response better than single SNPs,
since the combined effect of multiple linked variants determines overall P-gp
expression and function. Population frequencies vary
dramatically: the 3435C
allele ranges from 34% in some Asian populations to 90% in West African
populations.